Aerovate Therapeutics Stock Performance
| AVTE Stock | USD 2.52 0.02 0.80% |
The firm shows a Beta (market volatility) of 0.36, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aerovate Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aerovate Therapeutics is expected to be smaller as well. At this point, Aerovate Therapeutics has a negative expected return of -0.0359%. Please make sure to confirm Aerovate Therapeutics' treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to decide if Aerovate Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Aerovate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Aerovate Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.8 | Five Day Return 0.8 | Year To Date Return (6.32) | Ten Year Return (88.96) | All Time Return (88.96) |
1 | Aerovate Therapeutics Target of Unusually Large Options Trading - MarketBeat | 01/17/2025 |
2 | Disposition of 12495 shares by George Eldridge of Aerovate Therapeutics at 31.2291 subject to Rule 16b-3 | 01/24/2025 |
3 | Disposition of 10000 shares by Noyes Timothy P of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 | 03/11/2025 |
| Begin Period Cash Flow | 22.4 M | |
| Free Cash Flow | -56.9 M |
Aerovate |
Aerovate Therapeutics Relative Risk vs. Return Landscape
If you would invest 260.00 in Aerovate Therapeutics on December 24, 2024 and sell it today you would lose (8.00) from holding Aerovate Therapeutics or give up 3.08% of portfolio value over 90 days. Aerovate Therapeutics is currently does not generate positive expected returns and assumes 1.7726% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than Aerovate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aerovate Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aerovate Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aerovate Therapeutics, and traders can use it to determine the average amount a Aerovate Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0202
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AVTE |
Estimated Market Risk
| 1.77 actual daily | 15 85% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aerovate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aerovate Therapeutics by adding Aerovate Therapeutics to a well-diversified portfolio.
Aerovate Therapeutics Fundamentals Growth
Aerovate Stock prices reflect investors' perceptions of the future prospects and financial health of Aerovate Therapeutics, and Aerovate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aerovate Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | (14.86 M) | ||||
| Shares Outstanding | 28.98 M | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.91 X | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash And Equivalents | 151.99 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 675 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.85 X | ||||
| Book Value Per Share | 2.64 X | ||||
| Cash Flow From Operations | (56.78 M) | ||||
| Earnings Per Share | (2.99) X | ||||
| Market Capitalization | 73.04 M | ||||
| Total Asset | 127.42 M | ||||
| Retained Earnings | (163.42 M) | ||||
| Working Capital | 106.59 M | ||||
About Aerovate Therapeutics Performance
By analyzing Aerovate Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Aerovate Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aerovate Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aerovate Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.87) | (0.91) | |
| Return On Capital Employed | (0.98) | (1.02) | |
| Return On Assets | (0.87) | (0.91) | |
| Return On Equity | (0.91) | (0.87) |
Things to note about Aerovate Therapeutics performance evaluation
Checking the ongoing alerts about Aerovate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aerovate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aerovate Therapeutics generated a negative expected return over the last 90 days | |
| Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 10000 shares by Noyes Timothy P of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 |
- Analyzing Aerovate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aerovate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aerovate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aerovate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aerovate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aerovate Therapeutics' stock. These opinions can provide insight into Aerovate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |